These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31996683)

  • 21. The CD47-SIRPα Immune Checkpoint.
    Logtenberg MEW; Scheeren FA; Schumacher TN
    Immunity; 2020 May; 52(5):742-752. PubMed ID: 32433947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.
    Murata Y; Saito Y; Kotani T; Matozaki T
    Cancer Sci; 2018 Aug; 109(8):2349-2357. PubMed ID: 29873856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-SIRP
    Yanagita T; Murata Y; Tanaka D; Motegi SI; Arai E; Daniwijaya EW; Hazama D; Washio K; Saito Y; Kotani T; Ohnishi H; Oldenborg PA; Garcia NV; Miyasaka M; Ishikawa O; Kanai Y; Komori T; Matozaki T
    JCI Insight; 2017 Jan; 2(1):e89140. PubMed ID: 28097229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 25. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
    Sim J; Sockolosky JT; Sangalang E; Izquierdo S; Pedersen D; Harriman W; Wibowo AS; Carter J; Madan A; Doyle L; Harrabi O; Kauder SE; Chen A; Kuo TC; Wan H; Pons J
    MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
    de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
    Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody:CD47 ratio regulates macrophage phagocytosis through competitive receptor phosphorylation.
    Suter EC; Schmid EM; Harris AR; Voets E; Francica B; Fletcher DA
    Cell Rep; 2021 Aug; 36(8):109587. PubMed ID: 34433055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A; Chen J
    Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD47 Plays a Role as a Negative Regulator in Inducing Protective Immune Responses to Vaccination against Influenza Virus.
    Lee YT; Ko EJ; Lee Y; Lee YN; Bian Z; Liu Y; Kang SM
    J Virol; 2016 Aug; 90(15):6746-6758. PubMed ID: 27194758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
    Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
    PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential.
    Ma L; Zhu M; Gai J; Li G; Chang Q; Qiao P; Cao L; Chen W; Zhang S; Wan Y
    J Nanobiotechnology; 2020 Jan; 18(1):12. PubMed ID: 31931812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis.
    Gao L; Chen K; Gao Q; Wang X; Sun J; Yang YG
    Oncotarget; 2017 Apr; 8(14):22406-22413. PubMed ID: 27283989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor CD47 controls T cell alloresponses and is required for tolerance induction following hepatocyte allotransplantation.
    Zhang M; Wang H; Tan S; Navarro-Alvarez N; Zheng Y; Yang YG
    Sci Rep; 2016 May; 6():26839. PubMed ID: 27230788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.
    Weiskopf K; Anderson KL; Ito D; Schnorr PJ; Tomiyasu H; Ring AM; Bloink K; Efe J; Rue S; Lowery D; Barkal A; Prohaska S; McKenna KM; Cornax I; O'Brien TD; O'Sullivan MG; Weissman IL; Modiano JF
    Cancer Immunol Res; 2016 Dec; 4(12):1072-1087. PubMed ID: 27856424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer.
    Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z
    Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
    J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity.
    Wu J; Wu H; An J; Ballantyne CM; Cyster JG
    Proc Natl Acad Sci U S A; 2018 Jun; 115(26):6786-6791. PubMed ID: 29891680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
    Gholamin S; Mitra SS; Feroze AH; Liu J; Kahn SA; Zhang M; Esparza R; Richard C; Ramaswamy V; Remke M; Volkmer AK; Willingham S; Ponnuswami A; McCarty A; Lovelace P; Storm TA; Schubert S; Hutter G; Narayanan C; Chu P; Raabe EH; Harsh G; Taylor MD; Monje M; Cho YJ; Majeti R; Volkmer JP; Fisher PG; Grant G; Steinberg GK; Vogel H; Edwards M; Weissman IL; Cheshier SH
    Sci Transl Med; 2017 Mar; 9(381):. PubMed ID: 28298418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.
    Treffers LW; Zhao XW; van der Heijden J; Nagelkerke SQ; van Rees DJ; Gonzalez P; Geissler J; Verkuijlen P; van Houdt M; de Boer M; Kuijpers TW; van den Berg TK; Matlung HL
    Eur J Immunol; 2018 Feb; 48(2):344-354. PubMed ID: 28952147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling.
    Xu MM; Pu Y; Han D; Shi Y; Cao X; Liang H; Chen X; Li XD; Deng L; Chen ZJ; Weichselbaum RR; Fu YX
    Immunity; 2017 Aug; 47(2):363-373.e5. PubMed ID: 28801234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.